IN PRACTICE
The continued and aggressive marketing of breastmilk substitutes (BMSs) is a considerable impediment to improving breastfeeding. In this 'In Practice' article we, as academics, practitioners and child health advocates, describe contraventions of the regulations that protect breastfeeding in South Africa (SA) and argue that bold, proactive leadership to eliminate conflict of interest in respect of the BMS industry is urgently required, together with far greater investments in proven interventions to promote and support breastfeeding.
The 2016 Lancet Breastfeeding Series estimated that improved breastfeeding practices could prevent 72% of hospital admissions for diarrhoea and 57% for respiratory infections in low-and middleincome countries, and could have averted 823 000 deaths in the 75 Countdown countries in 2015. [1] Yet despite clear evidence of the benefits of exclusive and continued breastfeeding for children, women and society, far too few children in SA are breastfed. There is some urgency to improve breastfeeding rates in view of the profound life-course effects of breastfeeding on human health and all the Sustainable Development Goals. [2] In an effort to protect breastfeeding and respond to growing evidence of aggressive and inappropriate marketing strategies of BMS companies, [3, 4] the 34th World Health Assembly in 1981 adopted Resolution WHA34. 22 , which included the International Code of Marketing of Breast-milk Substitutes ('the Code') as a 'minimum requirement' to be adopted 'in its entirety' (118 nations voted in favour, and only the USA voted against). In 1982 Peru became the first country to adopt the Code as national legislation. Globally, 136 out of 194 countries have Code-related legislation, yet contraventions and violations persist in the face of weak monitoring and enforcement mechanisms. [5] In 2012, SA legislated the Code through the Regulations Relating to Foodstuffs for Infants and Young Children (R991) [6] in terms of section 15 (1) of the Foodstuffs, Cosmetics and Disinfectants Act, Act 54 of 1972, [7] following the Tshwane Declaration of Support for Breastfeeding. [8] R991 aims to protect and promote breastfeeding by regulating the inappropriate marketing of BMSs to 'remove commercial pressures from the infant feeding arena' , 'avoid creating any conflicts of interest or perverse incentives for individual health professionals' and 'ensure that financial support for professionals working in infant and young child health does not create conflicts of interest' .
formula at public sector health facilities. [9] A decade-long impasse in any public messaging in support of breastfeeding began, owing to fears of HIV transmission. With accumulating evidence from SA and other countries of the harmful effects of reduced breastfeeding rates on infant morbidity and mortality, [10] [11] [12] and several revisions of World Health Organization (WHO) guidance, SA changed its policies in 2011, adopting breastfeeding as the preferred feeding choice, and in 2012 ceased providing free infant formula while scaling up access to lifelong triple antiretroviral treatment. [8] Yet despite these policy initiatives to promote exclusive breastfeeding for the first 6 months in line with WHO guidelines, only 24% of SA's infants are still exclusively breastfed at 4 -5 months of age, [13] and the current rate of increase will fall short of the Global Nutrition Target of 50% exclusive breastfeeding in a country by 2025. [14, 15] This situation almost certainly contributes to SA's high under-5 mortality rate, compared with other upper-to middle-income countries, of 42 per 1 000 live births, and persistently high levels of stunting. [13] Greater multidimensional efforts in communities, health facilities and workplaces are therefore needed to promote, support and protect breastfeeding in the SA setting, particularly given concerns about the expansion of formula milk markets in the global South. [15] SA has seen a steady growth in infant formula sales over the past 15 years, from a retail value of ZAR1 billion in 2004 to ZAR4.2 billion in 2018 (a 33.3% per capita increase) and a forecast of over ZAR6 billion in 2023. [16] Formula is expensive, and unaffordable for the majority of SA families. Depending on the brand, the formula alone costs an estimated ZAR375 -561 a month, with potentially devastating implications for SA infants, 37% of whose families live below the food poverty line (households where the per capita income is <ZAR531 a month). [17] Consequently, many families opt for mixed feeding and/or dilute the formula to make it stretch further. While inadequate nutrition compromises infant health, keeping bottles clean is equally challenging, since 1 in 3 SA infants live in households that do not have drinking water on site. [13, 18] It is therefore not surprising that gastroenteritis (9%) and lower respiratory tract infections (17%) continue to be leading causes of under-5 mortality. [19] Furthermore, the most recent Child Healthcare Problem Identification Programme data show that 31% of children who died in hospital in 2015 had severe or acute malnutrition. [20] 
BMS industry contraventions of SA regulations to protect breastfeeding
The National Minister of Health signed R991 into law in 2012 for full implementation within 36 months. These regulations restrict how infant formula can be advertised and labelled, as well as stipulating under which circumstances industry is allowed to contribute sponsorship for paediatric/nutrition conferences. While R991 allows the BMS industry to contribute to a pooled fund for a conference or scientific meeting, direct sponsorship of individual delegates or speakers is prohibited and R991 explicitly 'excludes any promotion of designated products' to health professionals, restricts industry involvement to scientific and technical material, and prohibits the industry from making any 'health, medicinal or nutrition claims' . The National Department of Health (NDoH) has also produced guidelines for industry and healthcare personnel relating to R991. [21] Experience at the annual University of Cape Town Paediatric Refresher Course illustrates the extent of the problem. Between 2016 and 2018, persistent contraventions of the regulations were evident, including claims of health benefits, e.g. specific BMS brands to overcome 'Excessive Crying & Intestinal Gas' and for 'Treatment of Diarrhoea' and 'Hungry & Sleepless Infants' (Fig. 1) , and a BMS product launch of formula milk containing human milk oligosaccharides claiming to be 'Inspired by nature's perfection' (Fig. 1 ) -all of this despite very clear instructions to sponsors to comply with the regulations. Similar experiences have been reported at other universities.
In 2016, North-West University's School of Pharmacy hosted a symposium at which a BMS company sponsored a 'baby nutrition' workshop. This contravention of R991 was reported to the NDoH, and the session was subsequently cancelled by the organisers following receipt of a letter outlining the R991contraventions from the Deputy Director-General: HIV/AIDS, TB and Maternal, Child and Women's Health. In July 2019, at the combined South African Thoracic Society, Allergy Society of South Africa and Chest Wall International Group conference in Pretoria, a BMS company-sponsored breakfast symposium on human milk oligosaccharides ( Fig. 1 ) was cancelled on the morning by the symposium organisers after concerns were raised with the conference organisers and the NDoH regarding compliance with R991.
The BMS industry web of influence extends beyond marketing and promotion at health professional conferences, and includes a conscious intent to cultivate relationships with key thought leaders in nutrition and child health and to 'retain and reward' those who have high peer credibility and are positively disposed to the company brand. In 2012, a BMS company hired a consultancy firm to undertake a strategic stakeholder mapping exercise. The report targeted a number of thought leaders in nutrition and child health for engagement ( Fig. 2 ). [22] BMS industry sponsorship of universities to host nutrition symposia is an example of targeting of health professionals, such as the 14th Continuing Nutrition Education Symposium at the University of Pretoria (https://www. nestlenutrition-institute.org/country/za/) in September 2019 and similar examples from East Africa (https://www.nestlenutritioninstitute.org/country/za/news/article/2019/04/25/expansion-of-thethe-first-1-000-days-nurses-academy-by-nestl%C3%A9-nutritioninstitute-africa-east-africa).
The SA website of a multinational BMS company [23] (Fig. 1 ) currently contains incorrect information about the risks of HIV transmission through breastfeeding and the recommendations regarding infant feeding and HIV. The website recommends that women living with HIV should formula feed for 6 months and incorrectly states the risk of HIV transmission through breastfeeding as 10% (it is currently ~1% at 6 months with maternal antiretroviral therapy). [24] This information blatantly contradicts the current SA infant and young child feeding policy, which recommends 6 months of exclusive breastfeeding for all and continued breastfeeding up to 2 years and beyond, irrespective of HIV status. [25] The above are not isolated cases, but rather part of a global phenomenon, with a series of recent reports [5] documenting 'consistent, repeated, systematic violations' by the BMS industry.
Conflict of interest: Understanding the potential risks of industry funding
It is important to recognise that conflicts of interest exist within the individual or organisation -where, for example, funding from a BMS company has the potential to undermine health workers' fiduciary duty to protect and promote child health. While we may think that researchers are objective and immune to these conflicts, a Cochrane review [26] reported that despite academics' best intentions, conflicts of interest lead researchers to 'favour corporations either consciously or unconsciously' . This favouring does not necessarily imply collusion or corruption, but it becomes
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11 The baby should be tested for HIV using a PCR test, around 6 weeks after birth. If the baby shows signs of HIV infection before this time; the healthcare professional may decide to test the baby before 6 weeks of age. Before the birth, HIV-positive women should make a careful choice about feeding their babies. The recommendation is rather six months of full formula feeding, if adequate infant formula milk powder is available and a ordable; before weaning the baby with complementary foods and a breast milk substitute. Cup feeding is preferred, especially if bottles and teats cannot be properly cleaned and sterilised. If safe and adequate formula feeding is not possible; or an unsuitable option, even the one in ten chance of spreading HIV to the baby through breastfeeding is better than the risks of unhygienic and inadequate bottle feeding. Breastfeed exclusively for six months then introduce solids and a breast milk substitute at six months. Continue feeds with breast milk substitutes; complementary feeding and enriched family foods; as advised by the health professional or registered dietician.
Example of a contravention

Example of a contravention Description
Poster advertising infant formula at the 2018 UCT Paediatric Refresher Course. Claims are made on the poster that the formula relieves symptoms of colic, is a treatment for diarrhoea and can decrease regurgitation. Regulation Section 2: General labelling, composition, packaging and other manufacturing matters Section 2 (4) (a) (i)
The regulation states that 'no medicinal or nutrition claims shall be permitted in any manner for any designated product' .
Should a medicinal claim be made, the designated product should be controlled as per the Medicines and Related Substances Act with inclusion of the ingredient in said product.
Section 11: Material directed at healthcare providers
The regulation states that a manufacturer may provide technical scienti c material to healthcare providers provided that the information is restricted to current scienti c or technical matters and that the material bears no health or nutrition claims (in text or picture format).
Example of a contravention
Description BMS company advertising of a product with a claim that it is 'inspired by nature's perfection' due to its containing human milk oligosaccharides (2018 UCT Paediatric Refresher Course). The claim made is that the product is clearly comparable to human/breastmilk. Regulation
Section 3 (4)
'The container or label of any infant and follow-up formula or infant and follow up formula for special dietary management for infants, shall not include, in the brand name or any other phrases, the terms "maternalised", "humanized" or any derivative form of these terms, or any similar expression that may suggest a strong similarity between the product and breast milk. ' Section 11: Material directed at healthcare providers
Example of a contravention Description
Sponsorship of breakfast symposia for healthcare workers on the topic of human milk oligosaccharides. The breakfast is considered a bene t or gift. Regulation Sub-regulation 7 (2) (i) prohibits nancial contributions or sponsorship to healthcare personnel working in infant and young child feeding. Sub-regulation 7 (3) further states 'No person shall sell, promote, or advertise any designated product, including complementary foods, through health care personnel or health establishments. ' Among others, 'provision or o er, direct or indirect, of any gift in cash or in kind, contribution, or bene t to health care personnel' is viewed as a promotional practice. Sub-regulation 7 (5) prohibits production, distribution and presentation of educational information relating to infant and young children.
The guidelines to industry further state that industry is not allowed to 'provide meals and refreshments' at meetings where the agenda includes infant and young child nutrition and/or refers to designated products. 
Description of the contravention
Example of misinformation on a BMS company SA website Description
Incorrect information on a multinational BMS company's SA website, July 2019. The recommendation of 6 months of formula feeding for women living with HIV is incorrect according to SA policy. The one in ten chance of HIV transmission through breastfeeding is incorrect. Under current guidelines, which provide for lifelong antiretroviral treatment for all individuals living with HIV, the risk of postnatal HIV transmission through breastmilk is ~1% at 6 months. [24] The recommendation to stop breastfeeding at 6 months, for women opting to breastfeed, is also contrary to SA policy. Policy This does not directly contravene R991, but is contradictory to the South African Infant and Young Child Feeding Policy, [25] which recommends:
The policy recommendation that HIV-infected women should stop breastfeeding at 12 months is revised. HIV-infected women who are breastfeeding should be supported to adhere to antiretroviral therapy (ART), and should be counselled and supported to exclusively breastfeed their infants for the rst 6 months , life, to introduce complementary foods thereafter, and to continue breastfeeding for at least 2 years (pg 14 of the IYCF policy indicating the amendment is attached). This means that infant and young child feeding recommendations for HIV negative and HIV positive mothers are fully aligned. All healthcare workers are reminded of the importance of ensuring that all pregnant and breastfeeding HIV-infected mothers receive ART, together with adherence support. https://www.startstrong.nestle.co.za/hiv-infection-and-pregnancy Fig. 1 . BMS industry violations of the Regulations Relating to Foodstuffs for Infants and Young Children (R991) [6] and misinformation. Names of companies and individuals have been concealed. (BMS = breastmilk substitutes; UCT = University of Cape Town; SA = South African.)
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'difficult to distinguish subtle, unconscious bias from deliberately concealed impropriety' .
In 2014, the International Society of Social Paediatrics and Child Health adopted a position statement calling for 'the end of all sponsorship of paediatric educational meetings by the Baby Feeding Industry' and drew attention to the potential dangers arising from various types of industry sponsorship. [27] For example, industry sponsorship and/or branding of a child health-or nutrition-related conference creates the impression that an academic department or society publicly endorses formula feeding, while support for salaries, equipment and/or research means that a department will be indebted to the formula industry -tending to stifle any expression of doubt about the latter's products or practices.
With regard to paediatric and nutrition research, while there is indeed a place for evidence relating to the development of specialised formula milks, there are concerns about the influence of industry: a 2018 BMJ article raised concern about how 'Extensive links between the formula industry and the research, guidelines, medical education, and public awareness efforts around cow's milk protein allergy … have raised the question of industry driven overdiagnosis. ' [28] Between 2006 and 2016 in the UK, specialist formula prescriptions increased by 500% and National Health Service spending on these products increased by 700% from GBP8.1 million to GBP60 million.
It is important to recognise that these conflicts of interest extend beyond sponsorship of conferences to influence on national policy formulation and academia, where far more substantial offers of financial support may undermine the integrity of research and teaching programmes. Fig. 1 provides an example of an advertisement for a research study comparing three types of infant formula.
Implementing strategies to prevent and mitigate conflicts of interest
R991 makes provision for sanctions when its regulations are contravened. The penalties applicable to the contravention of any of the regulations are found in section 18 of the Foodstuffs, Cosmetics and Disinfectants Act. [7] It prescribes that '[a]ny person convicted of an offence under this Act shall be liable (a) on a first conviction, to a fine or to imprisonment for a period not exceeding six months or to both a fine and such imprisonment' . Yet in SA there is minimal monitoring, reporting or enforcement. There is an urgent need for clearly defined monitoring, reporting and enforcement mechanisms that have some traction to deter contraventions. It is also unclear who, besides the BMS company, is accountable for the contravention, and the role of event organisers and organising committees, in respect of conferences and meetings, requires clarity.
So how do health professionals go about addressing conflicts of interest? A first step towards creating greater awareness and understanding of conflicts of interest is to include teaching on ethics and practice in undergraduate and in-service health professional training. By not introducing these concepts into undergraduate education, health professionals enter practice at risk of judgement errors when confronted with BMS industry influence in clinical or academic contexts. R991 applies to both the public and the private sectors, and education and awareness of the regulations and conflicts of interest are therefore needed in both sectors, particularly with the forthcoming public-private contracting proposed in SA's National Health Insurance.
From an ethical standpoint, health professionals must declare any funding, contractual relationship or in-kind support from BMS companies in any public statement, publications or conference presentations. However, the optimal approach would be to adopt a clear and unequivocal position and refuse all industry funding of child health-or nutrition-related work if health professionals are to maintain professional integrity and safeguard the health of the most vulnerable women and children.
In February 2019, after an outcry against BMS sponsorship of its conference in Cairo, the UK Royal College of Paediatrics and Child Health issued a statement announcing that it would no longer accept any funding from the formula milk industry. It would continue to 'engage and work in partnership' with formula milk companies with regard to specialist formula milks, but without accepting any funding. [29] The College had received ~GBP40 000 a year from BMS companies through event sponsorship and advertising.
In March 2019, the BMJ (and its sister publications) stated their intent no longer to run infant formula advertisements: ' After decades of advertising breastmilk substitutes to readers of the BMJ, we have decided it is time to stop. ' [30] We call on SA health and nutrition journals to adopt similar advertising policies. 
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At its recent executive meeting, the South African Paediatric Association agreed in principle not to accept any further funding from BMS companies. Bold moves such as this are what are needed to send a clear message to an industry that is adept at finding loopholes and infiltrating audiences where they know they will have the greatest impact.
Now is an appropriate time for the child health and nutrition communities to pause and reconsider any relationships with the baby food industry, including funding for research, conferences and other educational initiatives, particularly when infant feeding and allergy are involved. We therefore call on academic departments and professional associations to demonstrate their commitment to protect breastfeeding from the commercial influence of BMS companies in southern Africa, and to adopt clear position statements that signal their intention to: (i) refuse any further offers of BMS industry sponsorship for academic conferences, research or teaching programmes; (ii) disclose current sources of BMS company funding of research and teaching programmes, and require upfront disclosure of funding sources in any publications or presentations arising therefrom; (iii) take active steps to minimise the impact of any existing conflicts of interest; (iv) educate health professionals, staff and students about the benefits of breastfeeding and measures to address the conflicts of interest associated with BMS funding;
(v) intensify efforts to promote, support and protect breastfeeding; and (vi) monitor implementation of R991 and the Code and report any contraventions to the NDoH.
Dedication. We dedicate this 'In Practice' article to Emeritus Professor David Sanders, who died following the acceptance of the article. David, a paediatrician and child health advocate, dedicated his life to improving the health and nutrition of children, especially the most vulnerable, through his research, writing, teaching and activism. A key focus of his work was the political economy of health and the role of transnational food companies in driving unhealthy dietary choices, including feeding of infants. The struggle for health will continue through the innumerable lives that he influenced across the globe.
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